Amgen's GDNF fails PD Phase II

AMGN said its glial-derived neurotrophic factor (GDNF) failed to meet the primary endpoint of symptom improvement at six months as defined by the UPDRS in a Phase II trial in 34 patients with advanced Parkinson's disease (PD). Full data are being submitted for presentation at the American Neurological Association meeting in October. All patients in the trial are receiving GDNF in an open-label extension study. ...